OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2014 to Q4 2025

Type / Class
Equity / Common stock ("Common Shares")
Symbol
OCUL on Nasdaq
Shares outstanding
212,883,456
Price per share
$12.14
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
188,183,067
Total reported value
$2,200,136,926
% of total 13F portfolios
0.02%
Share change
+30,908,827
Value change
+$370,626,610
Number of holders
213
Price from insider filings
$12.14
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +22% $371,574,057 +$142,354,542 31,785,634 +62% FMR LLC 30 Sep 2025
Deep Track Capital, LP 6.2% -35% $153,090,545 -$27,615,088 13,095,855 -15% Deep Track Capital, LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 7.3% $150,957,880 12,913,420 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
SUMMER ROAD LLC 5.7% $131,657,773 12,134,357 SUMMER ROAD LLC 04 Dec 2025
BlackRock, Inc. 5.8% $118,890,012 10,170,232 BlackRock, Inc. 30 Sep 2025
Opaleye Management Inc. 2.8% $34,305,750 4,342,500 Opaleye Management Inc. 31 Dec 2024

As of 30 Sep 2025, 213 institutional investors reported holding 188,183,067 shares of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL). This represents 88% of the company’s total 212,883,456 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 31,785,634 +62% 0.02% $371,574,056
VR ADVISER, LLC 6.2% 13,161,462 +3.1% 8.7% $153,857,491
Summer Road LLC 5.9% 12,579,657 -9.4% 99% $147,050,970
Deep Track Capital, LP 5.6% 11,932,137 -17% 3.9% $139,486,682
BlackRock, Inc. 5% 10,556,837 +0.1% 0% $123,409,426
Avoro Capital Advisors LLC 4.8% 10,250,000 +39% 1.6% $119,822,500
VANGUARD GROUP INC 4.3% 9,163,240 +9.2% 0% $107,118,275
TCG Crossover Management, LLC 2.9% 6,117,232 +15% 3.5% $71,510,442
CITADEL ADVISORS LLC 2.7% 5,703,781 +17% 0.05% $66,677,200
Point72 Asset Management, L.P. 2.2% 4,601,321 +142% 0.12% $53,789,442
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.9% 4,004,350 +2.9% 0.07% $46,810,852
MILLENNIUM MANAGEMENT LLC 1.8% 3,855,706 +3136% 0.04% $45,073,203
Paradigm Biocapital Advisors LP 1.6% 3,497,307 +2.3% 1.2% $40,883,519
STATE STREET CORP 1.6% 3,460,012 -1.4% 0% $40,447,540
ALLIANCEBERNSTEIN L.P. 1.6% 3,424,439 +2003% 0.01% $40,031,692
GEODE CAPITAL MANAGEMENT, LLC 1.6% 3,338,453 +1.7% 0% $39,032,331
Logos Global Management LP 1.5% 3,250,000 +48% 3.8% $37,992,500
DELTEC ASSET MANAGEMENT LLC 1.3% 2,762,459 -1.2% 5.3% $32,293,146
Octagon Capital Advisors LP 1.2% 2,624,000 +8.2% 4.8% $30,674,560
MORGAN STANLEY 1.2% 2,465,676 -4.1% 0% $28,823,760
Balyasny Asset Management L.P. 1% 2,189,276 +903% 0.05% $25,592,636
JANUS HENDERSON GROUP PLC 0.96% 2,048,500 +3729% 0.01% $23,957,208
Woodline Partners LP 0.78% 1,666,087 +122% 0.09% $19,476,557
MARSHALL WACE, LLP 0.75% 1,601,449 0.02% $18,720,939
Opaleye Management Inc. 0.75% 1,595,000 0% 2.6% $18,645,550

Institutional Holders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,001,192 $12,071,199 +$7,810,005 $12.14 14
2025 Q3 188,183,067 $2,200,136,926 +$370,626,610 $11.69 213
2025 Q2 156,434,424 $1,451,692,801 +$187,013,442 $9.28 182
2025 Q1 137,366,906 $1,007,015,604 +$22,122,134 $7.33 195
2024 Q4 133,836,935 $1,142,923,387 -$55,464,898 $8.54 177
2024 Q3 139,959,663 $1,219,693,896 +$26,591,052 $8.70 167
2024 Q2 137,374,655 $939,612,942 +$86,876,988 $6.84 148
2024 Q1 123,359,441 $1,120,804,208 +$453,790,279 $9.10 145
2023 Q4 73,706,225 $328,758,787 +$150,569,150 $4.46 118
2023 Q3 40,429,130 $126,952,212 -$14,507,076 $3.14 112
2023 Q2 43,457,924 $224,194,712 +$15,406,633 $5.16 132
2023 Q1 40,293,660 $212,326,580 +$6,217,594 $5.27 124
2022 Q4 39,631,821 $111,363,550 -$11,852,132 $2.81 110
2022 Q3 42,784,711 $177,641,770 -$6,246,780 $4.15 126
2022 Q2 44,283,851 $178,116,533 +$2,778,803 $4.02 121
2022 Q1 43,481,638 $215,332,400 +$8,618,176 $4.95 127
2021 Q4 41,528,139 $289,118,916 -$36,286,646 $6.97 137
2021 Q3 44,501,826 $445,218,082 -$45,732,043 $10.00 137
2021 Q2 48,348,304 $685,490,035 +$13,999,445 $14.18 146
2021 Q1 47,154,599 $773,686,821 -$65,718,337 $16.41 149
2020 Q4 50,434,472 $1,043,919,487 +$206,608,703 $20.70 146
2020 Q3 39,773,072 $302,720,116 +$7,274,447 $7.61 101
2020 Q2 38,676,765 $322,007,676 +$85,260,671 $8.33 103
2020 Q1 28,477,673 $140,961,353 +$17,928,044 $4.95 87
2019 Q4 25,199,716 $99,537,589 +$4,791,546 $3.95 77
2019 Q3 23,281,316 $70,779,921 +$1,143,980 $3.04 73
2019 Q2 22,700,375 $99,883,931 +$3,092,692 $4.40 66
2019 Q1 22,319,507 $88,607,906 +$2,352,091 $3.97 65
2018 Q4 21,483,102 $85,497,322 -$3,739,436 $3.98 66
2018 Q3 21,648,697 $148,941,295 -$1,204,780 $6.88 72
2018 Q2 22,017,576 $148,575,866 +$9,801,776 $6.75 69
2018 Q1 20,434,189 $133,026,813 +$45,596,053 $6.51 63
2017 Q4 13,505,162 $60,113,388 -$11,835,912 $4.45 67
2017 Q3 15,581,267 $96,508,272 -$1,101,751 $6.18 71
2017 Q2 15,456,517 $143,279,882 -$26,251,504 $9.27 71
2017 Q1 18,346,444 $170,228,516 +$20,289,375 $9.28 73
2016 Q4 17,394,280 $145,604,494 -$10,234,332 $8.37 76
2016 Q3 18,785,162 $129,054,713 -$2,936,943 $6.87 70
2016 Q2 19,471,110 $96,376,641 -$30,443,305 $4.95 74
2016 Q1 20,860,674 $201,445,609 -$1,629,571 $9.66 64
2015 Q4 21,056,974 $197,303,107 -$18,088,390 $9.37 71
2015 Q3 20,040,765 $281,768,540 +$49,654,282 $14.06 66
2015 Q2 16,138,941 $339,403,403 +$93,805,035 $21.03 71
2015 Q1 10,685,998 $448,639,275 +$240,805,053 $41.98 56
2014 Q4 5,006,746 $117,752,025 +$9,256,090 $23.52 36
2014 Q3 4,629,882 $69,305,000 +$69,305,000 $14.97 33